Donate For Public and Patients Store Search

S028 - Atopic Dermatitis

Saturday, March 2; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize the high burden of atopic dermatitis
  • Identify barrier and immune defects in atopic dermatitis that form the basis for new therapies
  • Use improved understanding of available and emergent therapies in making decisions on atopic dermatitis management

Description

This session provides an up-to-date overview about atopic dermatitis, new discoveries and new therapies. The session is directed towards dermatologists and other health care providers who treat adults and/or children with atopic dermatitis. Moderated by Dr. Amy Paller, topics to be reviewed are: i) The Burden of Atopic Dermatitis (Dr. Aaron Drucker); ii) AD Pathogenesis - the Epidermal Barrier (Drs. Lisa Beck and Liat Samuelov) and the Immune System (Dr. Emma Guttman-Yassky); iii) The Microbiome and AD (Dr. Heidi Kong); iv) Topical Therapy (Dr. Lawrence Eichenfield) and v) Systemic therapy (Dr. Eric Simpson).

Disclosures

  • Beck, Lisa A., MD: AbbVie – C(Fees); Allakos – C(Fees); AstraZeneca – C(Fees); Boehringer Ingelheim – C(Fees); Celgene Corporation – C(Fees); Eli Lilly and Company – C(Fees); GlaxoSmithKline – C(Fees); LEO Laboratories Ltd (LEO Pharma) – C(Fees); Medtronics – SH(ST); New York Stem Cell Foundation – C(Fees); Novartis – C(Fees); Pfizer Inc. – C(Fees), I(Grants/Research Funding), SH(ST); Realm Therapeutics – C(Fees), I(Grants/Research Funding); Regeneron – C(Fees); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Sanofi – C(Fees); UCB – C(Fees);
  • Drucker, Aaron Mark, MD: AbbVie – C(H), O(Grants/Research Funding); Eli Lilly and Company – SP(H); GlaxoSmithKline – O(Grants/Research Funding); Intarcia Therapeutics – C(H); Janssen Pharmaceuticals, Inc – C(H), O(Grants/Research Funding); Kallyope – C(H); Merck & Co., Inc – C(H), O(Grants/Research Funding), SP(H); Novartis – C(H); Novo Nordisk A/S – C(H), O(Grants/Research Funding), SP(H); Pfizer Inc. – C(H); Regeneron – O(Grants/Research Funding); Sanofi – O(Grants/Research Funding); Shire – O(Grants/Research Funding), O(IP); Zafgen – C(H);
  • Eichenfield, Lawrence F., MD: Abbvie – I(Grants/Research Funding); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana BioSciences – Data Safety Monitoring Board(H); Cutanea Life Sciences – C(H); Dermavant Sciences, Inc. – C(H); Dermira – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Forte – A(H); Galderma Laboratories, L.P. – C(H), I(Fees); Glenmark Pharmaceuticals, Inc. – Data Safety Monitoring Board(H); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); MatriSys Bioscience – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H); Pfizer Inc. – C(H), I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Fees); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Verrica Pharmaceuticals Inc – A(SO), C(H), I(Grants/Research Funding); Wiley-Blackwell – O(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Almirall – A(H), C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Asana Biosciences, LLC – A(H), C(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), C(H), I(Grants/Research Funding); Cara Therapeutics – A(H), C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Concert Pharmaceuticals – C(H), I(Grants/Research Funding); DBV Technologies – A(H), C(H); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), C(H), I(Grants/Research Funding); DS Biopharma – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding); EMD Serono – C(H); Escalier – A(H), C(H); FLX Bio – C(H); Galderma Research & Development, LLC – A(H), C(H), I(Grants/Research Funding); Glenmark Generics Inc. – A(H), C(H), I(Grants/Research Funding); Incyte Corporation – A(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – A(H), C(H), I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novan – A(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H), I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Sanofi – A(H), C(H); Sienna Biopharmaceuticals – A(H), C(H), I(Grants/Research Funding); UCB – I(Grants/Research Funding); Union Therapeutics – C(H), I(Grants/Research Funding);
  • Kong, Heidi H., MD, MHS: no financial relationships exist with commercial interests.
  • Paller, Amy S., MD: AbbVie – I(NC); Amgen – C(H), I(NC); Amicus Therapeutics – C(H); Boehringer Ingelheim – C(H); BridgeBio Pharma, LLC – A(H), C(H); Castle Creek Pharmaceuticals – C(H); Celgene Corporation – I(NC); Chameleon Communications – C(H); Dermavant Sciences – C(H); Dermira – C(H); Eli Lilly and Company – C(H); Expanscience – Speaker/Faculty Education(H); Forte Biosciences – C(H); Galderma Laboratories, L.P. – C(H); Janssen Pharmaceuticals, Inc – I(NC); Leo Pharma Inc – I(Grants/Research Funding); Menlo Therapeutics – A(H), C(H); MorphoSys AG – C(H); Novartis Pharmaceuticals Corp. – C(H); Pfizer Inc. – C(H); Regeneron – C(H); Sanofi/Regeneron – A(H); Stiefel a GSK company – C(H); TARGET Pharma – C(H); Theravance Biopharma – C(H); Union Therapeutics – C(H); Valeant Pharmaceuticals North America LLC – C(H); Verrica Pharmaceuticals Inc – C(H);
  • Samuelov, Liat, MD: no financial relationships exist with commercial interests.
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees), I(Grants/Research Funding); Boehringer Ingelheim – C(Fees); Demira – C(Fees); Dermavant Sciences – C(Fees); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Forte Biosciences – C(Fees); Galderma Laboratories, LP – I(Grants/Research Funding); Incyte Corporation – C(Fees); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Leo Pharma Inc. – C(Fees), I(Grants/Research Funding); Menlo Therapeutics Inc. – C(Fees); Merck – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Pierre Fabre Dermo Cosmetique France – C(Fees); Regeneron – C(Fees), I(Grants/Research Funding); Sanofi Genzyme – C(Fees); Valeant Pharmaceuticals International – C(Fees);
Schedule
Saturday, March 2
1:00 PM
Dr. Paller / Introduction
1:05 PM
Dr. Drucker / The Burden of Atopic Dermatitis: from Population to Bedside
1:35 PM
Dr. Beck and Samuelov / Pathogenesis: The Epidermal Barrier and its Role
2:00 PM
Dr. Guttman / Pathogenesis – The Immune System and Relevance to Targeted Therapeutics
2:30 PM
Dr. Eichenfield / Topical Therapy
3:05 PM
Dr. Kong / The Microbiome and Atopic Dermatitis: New directions in therapy?
3:35 PM
Dr. Simpson / Systemic therapy - What’s here/ what’s coming?
Event Details
  • Date
    Saturday, March 2
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 144A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Amy S. Paller, MD, FAAD
Speakers
  • Aaron Mark Drucker, MD, FAAD - Handout
  • Emma Guttman, MD, PhD, FAAD - Handout
  • Eric Lawrence Simpson, MD, FAAD
  • Heidi H. Kong, MD, MHS, FAAD - Handout
  • Lawrence F. Eichenfield, MD, FAAD
  • Liat Samuelov, MD - Handout
  • Lisa A. Beck, MD